

(56)

References Cited

FOREIGN PATENT DOCUMENTS

EC	SP99-3280	12/1999
EP	0000128	1/1979
EP	0104483	4/1984
EP	0415566	6/1991
EP	0779074	6/1997
EP	0936217	8/1999
GB	2031882	4/1980
JP	06-345724	12/1994
JP	7-242694	9/1995
JP	10-045773	2/1998
JP	11-140086	5/1999
JP	2002105067	4/2002
WO	WO 92/09279	6/1992
WO	WO 93/04688	3/1993
WO	WO 96/26208	8/1996
WO	WO 99/24038	5/1999
WO	WO 00/07193	2/2000
WO	WO 00/07629	2/2000
WO	WO 00/27394	5/2000
WO	00/35424	6/2000
WO	WO 01/012204	2/2001
WO	WO 02/00210	1/2002
WO	02/062330	8/2002
WO	WO 03/037332	5/2003
WO	WO 03/064410	8/2003
WO	WO 2004/009563	1/2004
WO	WO 2006/028342	3/2006
WO	WO 2006/055412	5/2006
WO	WO 2007/019153	2/2007
WO	2007/062028	5/2007
WO	WO 2008/089296	7/2008
WO	WO 2009/041798	4/2009
WO	WO 2010/030988	3/2010
WO	2011/162390	12/2011
WO	2012/005365	1/2012

OTHER PUBLICATIONS

- Arromdee et al., Epidemiology of Gout—Is the Incidence Rising, the *Journal of Rheumatology* 2002; 29:11, pp. 2403-2406.
- Baker et al., Serum uric acid and cardiovascular disease: Recent Development, and where do they leave us? *The American Journal of Medicine*, vol. 118 No. 8, pp. 816-826, Aug. 2005.
- Becker et al., Clinical Aspects of Monosodium Urate Monohydrate Crystal Deposition Disease (Gout). *Rheumatic Disease Clinics of North America*—vol. 14, No. 2, pp. 377-395, Aug. 1988.
- Becker et al., We can make Gout Management more successful now, *Current Opinion in Rheumatology*, vol. 20, pp. 167-172, 2008.
- Becker, M. et al., “A Phase 3 Randomized, Controlled, Multicenter, Double-Blind Trial (RCT) Comparing Efficacy and Safety of Daily Febuxostat (FEB) and Allopurinol (ALLO) in Subjects with Gout” [abstract], *Amer College Rheum.* (2008) Abstract No. L11.
- Becker, M.A. et al., A phase 3 study comparing the safety and efficacy of oral febuxostat and allopurinol in subjects with hyperuricemia and gout [abstract]. *Arthritis Rheum.* Dec. 2004; 50(12):4103-4104. Abstract No. L18.
- Becker, M.A. et al., “A safety and efficacy clinical trial of a novel non-purine selective inhibitor of xanthine oxidase, febuxostat in subjects with gout” [abstract]. *Ann Rheum Dis.* Jul. 2004; 63(Suppl 1):60. Abstract No. OP0007.
- Becker, M.A. et al., “Allopurinol intolerant patients treated with febuxostat for 4 years” [abstract]. *Arthritis Rheum.* Sep. 2006; 54(9 Suppl):S646-S647. Abstract No. 1605.
- Becker MA et al., Clinical efficacy and safety of successful long-term urate lowering with febuxostat or allopurinol in subjects with gout. *J Rheumatol.* (2009) 36(6):1273-1282.
- Becker, M.A. et al., Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy. *Nucleosides Nucleotides and Nucleic Acids.* Jun. 2008; 27(6):585-591.
- Becker, M.A. et al., Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers. *Nucleosides Nucleotides Nucleic Acids.* Oct. 2004; 23(8 & 9):1111-1116.
- Becker MA et al., Febuxostat compared with allopurinol in patients with hyperuricemia and gout, *N Engl J Med.* Dec. 2005;353(23):2450-2461.
- Becker, M.A. et al., “Febuxostat vs allopurinol controlled trial in subjects with hyperuricemia and gout (FACT): a multicenter, phase 3, randomized, controlled, double-blind clinical study” [abstract]. *Pharmacotherapy* Oct. 2005; 25(10):1488. Abstract No. 359E.
- Becker MA et al., Febuxostat, a novel non-purine selective inhibitor of xanthine oxidase, therapy in allopurinol intolerant patients [abstract]. *Arthritis Rheum.* Sep. 2004;50(9 Suppl):S336. Abstract No. 803.
- Becker, M.A. et al., “Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase, therapy in allopurinol intolerant patients” [abstract]. *J Natl Med Assoc.* Jun. 2005; 97(6):894.
- Becker MA et al., Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. *Arthritis Rheum.* Mar. 2005;52(3):916-923.
- Becker MA et al., Gout flare incidence in relation to average serum urate during the first year of urate-lowering therapy [abstract]. *Arthritis Rheum.* Sep. 2007;56 (9 Suppl):S322-S323. Abstract No. 758.
- Becker MA et al., Long-term urate-lowering therapy in subjects with gout—the EXCEL study [abstract]. *International Journal of Rheumatic Diseases.* 2008;11 (Suppl 1):A209. Abstract No. P1Q-07.
- Becker MA et al., Magnetic resonance imaging (MRI) in the quantitative assessment of gouty tophi [abstract]. *Arthritis Rheum.* Sep. 2003;48(9 Suppl):S528. Abstract No. 1344.
- Becker, M.A. et al., “Magnetic resonance imaging of gouty tophi during treatment with febuxostat, a nonpurine selective inhibitor of xanthine oxidase” [abstract]. *J Natl Med Assoc.* Jun. 2005; 97(6):883.
- Becker MA et al., Reduction in gout flares in subjects with chronic gout treated with febuxostat or allopurinol for 52-weeks: FACT trial [abstract]. *Arthritis Rheum.* Sep. 2005;52(9 Suppl):S108. Abstract No. 202.
- Becker, M.A. et al., “The long-term clinical benefits of febuxostat vs allopurinol in subjects with gout: interim analysis of the EXCEL trial, an ongoing phase 3, open-label extension study” [abstract]. *Ann Rheum Dis.* Jul. 2006; 65(Suppl 2):431. Abstract No. FRI0484.
- Becker MA et al., Urate-lowering pharmacotherapy with febuxostat (FEB) or allopurinol (ALLO) in African-American subjects with gout [abstract]. *Arthritis Rheum.* Sep. 2007;56(9 Suppl):S637. Abstract No. 1622.
- Becker, M.A. et al., “Urate-lowering pharmacotherapy with febuxostat or allopurinol in black-american subjects with gout” [abstract]. *Ann Rheum Dis.* Jul. 2007; 66(Suppl II):231. Abstract No. THU0340.
- Becker, M.A. et al., “Urate-lowering therapy (Febuxostat [FEB] or Allopurinol [ALLO]) in subjects with gout: interim results from the febuxostat comparative extension long-term study (EXCEL)” [abstract]. *Ann Rheum Dis.* Jul. 2007; 66(Suppl II):230-231. Abstract No. THU0339(757).
- Beers, M.H. et al. “221 / Urinary Calculi,” *The Merck Manual of Diagnosis and Therapy*, (1999) pp. 1838-1840.
- Beers, M.H. et al. “55 / Crystal-Induced Conditions,” *The Merck Manual of Diagnosis and Therapy*, (1999) pp. 460-464.
- Berge et al., “Pharmaceutical salts,” *J. Pharm. Sci.* (1977) 66:1-19.
- Berry, C.E. et al., “Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications,” *J Physiol* (2004), 555.3:589-606.
- BOF-4272, Drug Print Report, Printed from Website http://release2.id.../report.print_disply?i_query_id=1214721&template=DrugPrint&id=852, Jan. 17, 2003.
- Borstad et al., Colchicine for Prophylaxis of Acute Flares When Initiating Allopurinol for Chronic Gouty Arthritis, *The Journal of Rheumatology* 2004, 31:12, pp. 2429-2432.
- Braunwald, Biomarkers in Heart Failure, *N Eng J Med* 358;20, pp. 2148-2148 www.nejm.org May 15, 2008, Downloaded from www.nejm.org at Abbott on May 21 2008. Copyright 2008 Massachusetts Medical Society.
- Burrell, L.M. “A Risk-Benefit Assessment of Losartan Potassium in the Treatment of Hypertension,” *Drug Safety* (1997) 16(1):56-65.